Tremendous clinical outcomes have been achieved for patients with B-cell lymphoma and acute lymphoblastic leukemia (ALL) who received autologous CD19-targeted CAR-T cells [4–8]. Here, CD19 is linked to acute lymphoblastic leukemia.